An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announced an underwritten public offering of common shares, with the company intending to sell all the shares. The offering includes a 30-day option for the underwriters to purchase additional shares. The net proceeds will be used for research and development, capital expenditures, and general corporate purposes. The Benchmark Company LLC is the sole book-running manager for the offering.
Positive
None.
Negative
None.
VICTORIA, British Columbia--(BUSINESS WIRE)--
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), today announced that it intends to offer and sell common shares in an underwritten public offering. All of the common shares in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares offered in the public offering solely to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The Company intends to use the net proceeds from the proposed offering for research and development; capital expenditures, including expansion of existing laboratory facilities; and working capital and general corporate purposes.
The Benchmark Company LLC is acting as the sole book-running manager for the offering.
The securities will be offered and sold pursuant to a shelf Registration Statement on Form F-3 (File No. 333-273197) that was declared effective by the United States Securities and Exchange Commission (the “SEC”) on July 14, 2023. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting The Benchmark Company, LLC, 150 East 58th St., 17th Floor, New York, NY 10155, by telephone at 212-312-6700 or by email at prospectus@benchmarkcompany.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in Canada or any other state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. Forward–looking statements in this press release include statements related to: the offering, including the timing, pricing and details thereof; the over-allotment option; and expected use of proceeds from the offering. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions, the satisfaction of customary closing conditions related to the public offering including as to whether or when the offering may be completed, the impact of general economic, industry or political conditions in the United States, Canada or internationally and those described under the heading “Risk Factors” in the prospectus supplement related to the offering. You should also consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. These forward–looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
What did ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) announce?
ImmunoPrecise Antibodies Ltd. announced an underwritten public offering of common shares.
What is the purpose of the offering?
The net proceeds from the proposed offering will be used for research and development, capital expenditures, including expansion of existing laboratory facilities, and working capital and general corporate purposes.
Who is acting as the sole book-running manager for the offering?
The Benchmark Company LLC is acting as the sole book-running manager for the offering.
Where can I find more information about the offering?
More information about the offering, including the terms, will be available on the SEC's website at www.sec.gov or by contacting The Benchmark Company, LLC.
What are the risks associated with the offering?
The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
